Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Engelhardt

Showing results (131-140 of 255) with videos related to

Pageof 26
Sort By:
Infection and Immunity|July 23, 1998
A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infectionJ Staczek, H E Gilleland, L B Gilleland, et al.
Cornea|January 7, 2017
Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific MetricYuna Rapoport, Thomas Freeman, Tatsuki Koyama, et al.
Behring Institute Mitteilungen|February 1, 1997
Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosaH E Gilleland, L B Gilleland, J Staczek, et al.
Vaccine|October 10, 2020
Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret modelKate Guilfoyle, Diane Major, Sarah Skeldon, et al.
Influenza and Other Respiratory Viruses|October 30, 2019
Biosafety risk assessment for production of candidate vaccine viruses to protect humans from zoonotic highly pathogenic avian influenza virusesLi-Mei Chen, Ruben O Donis, David L Suarez, et al.
Plos One|September 3, 2024
Presenting decision-relevant numerical information to Dutch women aged 50-70 with varying levels of health literacy: Case example of adjuvant systemic therapy for breast cancerInge S van Strien-Knippenberg, Daniëlle R M Timmermans, Ellen G Engelhardt, et al.
Bone Marrow Transplantation|October 8, 2013
Six-month freedom from treatment failure is an important end point for acute GVHD clinical trialsS Sengsayadeth, B N Savani, M Jagasia, et al.
Antibodies (Basel, Switzerland)|September 24, 2019
Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B HemagglutininWalter Ramage, Tiziano Gaiotto, Christina Ball, et al.
Mutation Research|March 24, 2004
Assessment of the performance of the Ames II assay: a collaborative study with 19 coded compoundsS Flückiger-Isler, M Baumeister, K Braun, et al.
Journal of Virology|November 1, 1995
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virusT Muster, B Ferko, A Klima, et al.
Pageof 26

Showing results (131-140 of 255) with videos related to

Sort By:
Pageof 26
Infection and Immunity|July 23, 1998
A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infectionJ Staczek, H E Gilleland, L B Gilleland, et al.
Cornea|January 7, 2017
Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific MetricYuna Rapoport, Thomas Freeman, Tatsuki Koyama, et al.
Behring Institute Mitteilungen|February 1, 1997
Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosaH E Gilleland, L B Gilleland, J Staczek, et al.
Vaccine|October 10, 2020
Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret modelKate Guilfoyle, Diane Major, Sarah Skeldon, et al.
Influenza and Other Respiratory Viruses|October 30, 2019
Biosafety risk assessment for production of candidate vaccine viruses to protect humans from zoonotic highly pathogenic avian influenza virusesLi-Mei Chen, Ruben O Donis, David L Suarez, et al.
Plos One|September 3, 2024
Presenting decision-relevant numerical information to Dutch women aged 50-70 with varying levels of health literacy: Case example of adjuvant systemic therapy for breast cancerInge S van Strien-Knippenberg, Daniëlle R M Timmermans, Ellen G Engelhardt, et al.
Bone Marrow Transplantation|October 8, 2013
Six-month freedom from treatment failure is an important end point for acute GVHD clinical trialsS Sengsayadeth, B N Savani, M Jagasia, et al.
Antibodies (Basel, Switzerland)|September 24, 2019
Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B HemagglutininWalter Ramage, Tiziano Gaiotto, Christina Ball, et al.
Mutation Research|March 24, 2004
Assessment of the performance of the Ames II assay: a collaborative study with 19 coded compoundsS Flückiger-Isler, M Baumeister, K Braun, et al.
Journal of Virology|November 1, 1995
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virusT Muster, B Ferko, A Klima, et al.
Pageof 26